Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.996 -0.034 (-1.12%)

Streaming Delayed Price Updated: 9:54 AM EDT, Sep 9, 2026 Add to My Watchlist

Price and Volume

Volume	156,667
Open	3.060
Bid (Size)	2.990 (800)
Ask (Size)	3.000 (700)
Prev. Close	3.030
Today's Range	2.975 - 3.060
52wk Range	1.660 - 4.537
Shares Outstanding	81,632,619
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Today 9:00 EDT

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 ↗

Today 7:02 EDT

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial...

Via MarketBeat

Performance

YTD	+46.1%	+46.1%
1 Month	+6.6%	+6.6%
3 Month	+13.1%	+13.1%
6 Month	+13.5%	+13.5%
1 Year	+7.4%	+7.4%

More News

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

September 08, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

September 01, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine (NASDAQ:EDIT) Beats Q2 Estimates, but One-Time Revenue Boost Masks Underlying Momentum ↗

August 05, 2026

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

August 31, 2026

Via Chartmill

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

August 05, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

August 04, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗

May 31, 2026

Via The Motley Fool

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

May 28, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

May 26, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Tuesday? ↗

May 26, 2026

Via Chartmill

Editas Medicine Announces Proposed Public Offering

May 26, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

May 26, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

May 14, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces First Quarter 2026 Results and Business Updates

May 05, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

April 27, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

March 27, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Is Editas Medicine Going to $0? ↗

March 17, 2026

Via The Motley Fool

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

March 09, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

February 23, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas (EDIT) Q2 2024 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗

November 10, 2025

Via Chartmill

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

November 10, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

Via TokenRing AI

Frequently Asked Questions

Is Editas Medicine, Inc. - Common Stock publicly traded?

Yes, Editas Medicine, Inc. - Common Stock is publicly traded.

What exchange does Editas Medicine, Inc. - Common Stock trade on?

Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Editas Medicine, Inc. - Common Stock?

The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market

What is the current price of Editas Medicine, Inc. - Common Stock?

The current price of Editas Medicine, Inc. - Common Stock is 2.996

When was Editas Medicine, Inc. - Common Stock last traded?

The last trade of Editas Medicine, Inc. - Common Stock was at 09/09/26 09:54 AM ET

What is the market capitalization of Editas Medicine, Inc. - Common Stock?

The market capitalization of Editas Medicine, Inc. - Common Stock is 244.57M

How many shares of Editas Medicine, Inc. - Common Stock are outstanding?

Editas Medicine, Inc. - Common Stock has 245M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.